Khosla Ventures leads $50 million Series B for Bengaluru’s Even Healthcare as it pivots to run its own hospitals

Bengaluru-based managed care startup Even Healthcare announced on October 19, 2026 that it has raised a $50 million Series B round led by existing backer Khosla Ventures, with participation from Alpha Wave. The financing, disclosed to the market today, values the company at roughly $300 million, about three times its valuation 18 months earlier, and brings total capital raised to more than $120 million.

Why the round matters

The raise gives Even fresh capital to accelerate a strategic shift that the company began testing this year. Instead of relying primarily on partner hospitals to deliver care, Even is increasingly leasing and operating its own hospital facilities. Company founders and investors say that owning care sites lets Even align incentives for clinicians and managers around patient outcomes rather than volumes of tests and procedures.

India’s hospital market has long been structured so that higher service volumes often translate into higher revenue for operators and individual providers. Even’s model pays doctors fixed salaries and ties any bonuses to patient reported outcomes, while management compensation is not linked to procedural volume. According to the company, its hospitals in Bengaluru have achieved lower readmission rates and shorter lengths of stay compared with industry averages, and the new capital will fund a planned rollout of five additional hospitals in the city over the next six months.

Investor rationale and scrutiny

Khosla Ventures, which first backed Even at seed stage, led the new round because it sees the combination of financing, technology, and owned-delivery infrastructure as a way to restructure economics across India’s fragmented private healthcare market. Vinod Khosla and partners framed the investment as a bet on models that reward better health over higher utilization, pointing to Even’s early clinical and economic data as the basis for conviction.

For venture investors, the attraction is twofold. First, successful demonstration of lower-cost, outcomes-oriented care could unlock large, repeatable markets across Indian cities where private hospital chains dominate. Second, vertically integrated care creates levers for long term revenue and margin improvement if patient acquisition and retention scale as planned.

Financials, risks and recent restructuring

The injection of growth capital comes against a backdrop of persistent losses and a recent workforce restructuring. Public filings and company disclosures show Even reported significant net losses in the 2025 fiscal year even as revenue grew, and the startup undertook a layoff in August 2026 that affected several hundred employees. Company leadership has said the restructuring included severance and extended benefits for those impacted, while management described the moves as necessary to refocus the business for capital efficient expansion.

Even’s leadership has argued the company could become cash flow positive if it paused expansion, but it has chosen to deploy capital into opening and fitting out hospital sites. That strategy raises classic tension points for capital intensive healthcare ventures: if new hospitals reach operating scale and maintain claimed outcomes, Even could validate the model and improve unit economics. If expansion stalls or outcomes diverge from reported benchmarks, the company could face a longer path to profitability and additional financing pressure.

What this means for India’s healthcare startup landscape

The Series B places Even among a crowded set of startups in India aiming to reduce the country’s out of pocket healthcare burden through subscription, integrated primary care, and fixed price procedural offerings. Investors have recently shown interest in businesses that can coordinate care end to end, because continuity and prevention can reduce expensive hospital admissions and diagnostic overservice.

Even’s decision to run hospitals directly is a departure from lighter asset models and signals a willingness to build capital intensive infrastructure where investors believe the unit economics will ultimately reward scale. The outcome will matter beyond Bengaluru, because replicable success could encourage similar plays in other Indian metros and change how insurers negotiate for prices and outcomes.

Next steps

The company plans to deploy proceeds toward opening five hospitals in Bengaluru within six months, and it will continue to measure patient recovery with standard clinical scoring tools it has published publicly. Investors and industry watchers will be watching operating margins, readmission and complication metrics, and whether the new hospitals meet the timeline and outcome claims the founders have made.

Even Healthcare’s raise and expansion plans are also likely to prompt closer scrutiny from insurers, regulators, and incumbent hospital operators, making execution and transparency central to whether the model shifts incentives across India’s private healthcare market or remains a Bengaluru focused experiment.